ABUS vs JD · P/E 5.4, rev $6.2M vs P/E 7.6, rev $187.20B
Arbutus Biopharma Corp (ABUS) versus JD.com Inc Adr (JD) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
JD.com Inc Adr (JD) is a internet retail company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported JD revenue for 2025-12-31 was $187.20B. Net income was $3.31B. Revenue was up 17.9% from 2024-12-31 to 2025-12-31. JD currently screens at market cap $45.56B and trailing P/E 7.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. JD currently screens at market cap $45.56B and trailing P/E 7.6.
Not investment advice. Open the ABUS and JD stock pages for the full models.
Not investment advice.